The U.S. Food and Drug Administration has authorized hydroxychloroquine for emergency use for the treatment of patients with COVID-19 infection. Efficacy of the drug for COVID-19 is supported by anecdotal evidence and Donald Trump, but the approval is considered controversial. Novartis/Sandoz has donated 30 million doses and Bayer has donated 1 million tablets of chloroquine phosphate. Read More
Latest News
MS and coronavirus have a long history
April 9, 2020The human coronavirus (HCoV) is now considered an emerging pathogen but its links to multiple sclerosis date back some 40 years. Read More
Slide deck: COVID-19 – Epidemiology in Canada (April 7, 2020)
April 7, 2020Summary of epidemiology, testing and mortality rate; Canada and world statistics.
MS treatment recommendations during COVID-19 pandemic
March 30, 2020The Canadian Network of MS Clinics has posted a Q&A for patients with multiple sclerosis. Included are the group’s recommendations (see link below) for disease-modifying therapies (DMTs). Not immunosuppressant: Beta-interferons (Avonex, Betaseron/Extavia, Rebif, Plegridy), glatiramer acetate (Copaxone, Glatect), teriflunomide (Aubagio), and minocycline. Read More